Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus
Top Cited Papers
Open Access
- 1 April 2014
- journal article
- review article
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 27 (2), 264-301
- https://doi.org/10.1128/cmr.00101-13
Abstract
SUMMARY Streptococcus pyogenes , also known as group A Streptococcus (GAS), causes mild human infections such as pharyngitis and impetigo and serious infections such as necrotizing fasciitis and streptococcal toxic shock syndrome. Furthermore, repeated GAS infections may trigger autoimmune diseases, including acute poststreptococcal glomerulonephritis, acute rheumatic fever, and rheumatic heart disease. Combined, these diseases account for over half a million deaths per year globally. Genomic and molecular analyses have now characterized a large number of GAS virulence determinants, many of which exhibit overlap and redundancy in the processes of adhesion and colonization, innate immune resistance, and the capacity to facilitate tissue barrier degradation and spread within the human host. This improved understanding of the contribution of individual virulence determinants to the disease process has led to the formulation of models of GAS disease progression, which may lead to better treatment and intervention strategies. While GAS remains sensitive to all penicillins and cephalosporins, rising resistance to other antibiotics used in disease treatment is an increasing worldwide concern. Several GAS vaccine formulations that elicit protective immunity in animal models have shown promise in nonhuman primate and early-stage human trials. The development of a safe and efficacious commercial human vaccine for the prophylaxis of GAS disease remains a high priority.Keywords
This publication has 173 references indexed in Scilit:
- CXCL9/Mig Mediates T cells Recruitment to Valvular Tissue Lesions of Chronic Rheumatic Heart Disease PatientsInflammation, 2013
- Evolution of diversity in epidemics revealed by analysis of the human bacterial pathogen group A StreptococcusEpidemics, 2011
- New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococciVaccine, 2011
- Streptococcal Upper Respiratory Tract Infections and Exacerbations of Tic and Obsessive-Compulsive Symptoms: A Prospective Longitudinal StudyJournal of the American Academy of Child & Adolescent Psychiatry, 2011
- Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equiVaccine, 2009
- An intrinsic pattern of reduced susceptibility to fluoroquinolones in pediatric isolates of Streptococcus pyogenesDiagnostic Microbiology and Infectious Disease, 2008
- The IL-8 Protease SpyCEP/ScpC of Group A Streptococcus Promotes Resistance to Neutrophil KillingCell Host & Microbe, 2008
- Severe Group A Streptococcal Infections Associated with a Toxic Shock-like Syndrome and Scarlet Fever Toxin AThe New England Journal of Medicine, 1989
- Resurgence of Acute Rheumatic Fever in the Intermountain Area of the United StatesThe New England Journal of Medicine, 1987
- Effect of antibiotic therapy on the clinical course of streptococcal pharyngitisThe Journal of Pediatrics, 1985